sessions are expected as compared to the exercise group? Page 12, table 2, sick-leave is not listed, and how is it estimated? According to a previous study (Grovle L, Haugen A et al.) patients reliably report their current sickness benefit status but not the number of days on sick-leave.
The trial has three related primary outcomes: arm activity pain, rest pain, and acceptable symptom intensity at 24 months. This is acceptable in my opinion, while others had preferred a self-reported pain disability index. Y Roe et al. (2016) published a comprehensive review of the most frequent outcomes using ICF taxonomy. My most important objection is the choice of 15 points as the minimally clinically important difference (MCID). MCID is not an exact estimate because it is calculated by using the most subjective post-treatment global evaluation as a gold standard. For neck and back pain MCID of VAS-pain is always higher than for an index made from a set of questions. Surprisingly MCID for shoulder pain is estimated to 15, lower than for relevant shoulder scores (see Ekeberg et al). Another way of evaluating the minimally clinically important difference is to ask the patient on beforehand, in this case: would you prefer surgery with a benefit of 15 point reduction of pain on a 0-100 scale?
Also the choice of 30 as an acceptable state may represent a problem. How many of the included patients have a preoperative score of 30 to 45? Others have used patients reporting excellent or good as an acceptable state (by example Brox et al 1999) which is probably not much different from < 30, although possibly a stronger criterium.
The study includes three pre-specified subgroup hypotheses (page 19/20) . Analyses this hypotheses are just exploring and results are rarely important (see Pocock, NEJM 2016) . Nevertheless, when subgroups are included I miss a fourth hypothesis: patients on sick leave versus patients not on sick leave (Koljonen et al 2009 , Brox et al 1996 and 1999 .
Under limitations (page 25) it is reported that 14 patients were excluded because of A-C arthrosis or intra-articular findings. It is normally wrong to exclude patients after randomisation because it reduces the effect of randomisation, Fortunately exclusion includes only a small percentage of patients. Surgeons often believe that they can observe the painful lesion during arthroscopy, but this is not possible, pain and morphology are weakly correlated. This is a pragmatic trial and it is difficult to handle various surgeons who argue that this patient has to be excluded. Still only the clinical criteria should have been applied in order to reduce bias. * Clinical signs of full thickness rotator cuff ruptur would render exclusion. In my experience it would be impossible to ascertain a non-existing full thickness supraspinatus rupture in a patient with subacromial pain. I suggest that this is changed as I assume that the authors intend patients with Clinical signs of a major rupture resulting in marked weakness in any of the examined muscles? Later on apparently all patients underwent MRI with contrast and this was the final decision for eligibility? * Was fulfillment of all inclusion criteria mandatory? In that case, what is the reliability of item 5) isometric tests? Are they at all necessary? * Timing of steroid injections in relation to inclusion? * Calcific deposits allowed? Disregarded? * During the surgery apparently some patients were subjected to a partial bursetomy which reportedly may be a treatment for subacromial pain in itself. How is that managed in the analysis? * Was sucessful blinding controleld and assured? * "adequate relief of symptoms" at 6 months would allow crossover and change of treatment. If for instance a patients that underwent ASD was unsatisfied with the outcome, in what way was then treatment changed? Was the patient excluded or unblinded and regarded as a failure? How could blinding of the assessor be continued in such a situation? * How was inadequate relief of symptoms determined?
REVIEWER
Harvinder pal Singh University of Leicester United Kingdom REVIEW RETURNED 08-Oct-2016
GENERAL COMMENTS
Protocol appears to have been published after the significant portion of the project has been completed as some data appears to have been analysed already, Like on page 25 first paragraph, "Despite thorough preoperative screening...... (n=13)). Does it need to be included.
Page 17: Recruitment rate: Does this need to be published in the protocol of the study? Also the use of was and were in the paragraph gives the impression, study analysis is already complete.
The authors have not discussed about night pain that these patients very commonly suffer and can be the presenting complaint. Authors have covered it by asking patients to comment about the shoulder pain in last 24 hours but night pain could specifically be discussed as the presenting problem in most patients.
Page 2 Paragraph 2, The biggest difference between this study and the CSAW trial seems to be the Primary outcome measure. That could be mentioned in this paragraph.
Page 12 Para 1: 'Deliberating', does it need to be debilitating?
Page 16, Paragraph 2: Authors jump between present tense and past tense in this article. One example is use of was " each follow-up was documented" and page 16 para 1: 99% followup was achieved. Is this a publication of protocol or early results.
Why was the allocation for surgery versus physiotherapy kept as 2:1, Its limitations could be discussed in the limitations section.
Authors have not addressed how the partial tears would be addressed in the protocol, would they be excluded or included when assessing patients during surgery.
Would patients be included if they had bilateral disease or would only one shoulder be included?
VERSION 1 -AUTHOR RESPONSE
Comments from the Reviewer Number 1: ** Shoulder pain is next to low back pain and neck pain the most common musculoskeletal condition. Subacromial pain syndrome, rotator cuff disease or tendinosis often referred to as the impingement syndrome is the major diagnosis. Paradoxically, surgical treatment has exploded after a trial in BMJ in 1993 found that it was not more effective than exercises. Later studies have replicated this finding, but current overuse of surgery has not decreased.
The present protocol describes a sham controlled trial evaluating the effectiveness of surgery. The secondary aim is to compare surgical results to physiotherapy guided exercises. This trial is highly warranted and the protocol describes a gold standard design even using blinded interpretation of results and writing of the manuscript. Patients are already included according to the estimated sample size and follow-ups are continued until the last 2-year follow-up is completed. The protocol is very interesting and of excellent quality in my opinion.
Authors' response: We thank the reviewer for the careful review of our paper and an attentive summary of the prevailing status on the treatment of SIS. We appreciate the positive general remarks on our paper and particularly the insightful suggestions for improvement. **Abstract: A visual analogue scale (0-100) means that a scale is used as an analogue for pain intensity. To express this in mm is not the point, in my opinion it is better to delete mm.
Authors' response: Thank you for this attentive suggestion. We agree with the reviewer's suggestion (to delete "mm").
Authors' action: We have deleted "mm" from the VAS scale.
In addition, this suggestion by the reviewer also made us realize that we have not defined the word descriptors of the VAS scale properly. Accordingly, we have revised our Materials and Methods as follows (page 13, under the section on VAS): "Shoulder pain was assessed on a 100 mm scale ranging from 0 (no pain) to 100 (extreme pain)". Later on, format 0-100, is used. ** Introduction, page 5: Subacromial pain syndrome was used by K Engebretsen et al in BMJ in 2009, long before the referred guideline was published.
Authors' response: We thank the reviewer for reminding us of the history of the term "subacromial pain syndrome". ** The introduction suggests that surgery may be either therapeutical, placebo (or both) while neither the role or evidence of exercises is clearly reported. Also the similar ongoing UK trial lack the exercise arm.
Authors' response: We thank the reviewer for pointing out the limited discussion on the role/evidence of exercise therapy on SIS and also for highlighting that the inclusion of an exercise therapy group is an obvious difference/distinct feature between our trial and that of the CSAW.
Authors' action: Prompted by the reviewer's remarks, we have rephrased the Introduction as follows (page 4, 2nd para.): "Remarkably, there is a stark absence of evidence from high-quality controlled trials to support the existing practice of performing subacromial decompression for patients with SIS. Two recent systematic reviews concluded that subacromial decompression provides no superior benefits in terms of pain relief, function, or quality of life compared to non-surgical treatment 12,13. There is even a placebo controlled trial to show the beneficial effect of exercise therapy over placebo physiotherapy.14" ** Methods, page 8 and 9, table 1, sick leave is not listed.
Authors' response: Our baseline assessment included the following question: "Have the shoulder symptoms limited your ability to work normally?", with response options: "yes" or "no". However, unfortunately we did not specifically inquire about sick leave in our baseline questionnaire.
Authors' action: No action. ** Page 11, postoperative care is briefly described, how many physiotherapy sessions are expected as compared to the exercise group?
Authors' response: Participants in the exercise therapy (ET) group had 15 visits to an independent physiotherapist for guidance and monitoring of the progress. In the surgical groups (both ASD and DA groups), in turn, the postoperative care was pragmatic in nature: In essence, all surgically treated participants received one visit to an independent physiotherapist for guidance and instructions for home exercises. They were also given a referral to the physiotherapy unit of their own participating centre, but adherence (the number of physiotherapy visits) was not monitored in the ASD and DA arms.
Authors' action: The above noted has now been added to the text as follows: "In both ASD and DA groups, the postoperative rehabilitation was identical. All surgically treated participants received one visit to an independent physiotherapist for guidance and instructions for home exercises. Subsequent rehabilitation was carried out according to the standardized rehabilitation protocols of the participant centres." (page 11, under the title: "Postoperative care"). Regarding the reviewer's query on how many of the included patients have a preoperative score of 30 to 45: Although we have made a deliberate decision not to analyze any of the trial data beforehand, we decided to address this specific query. Our preliminary exploration demonstrated an evident inconsistency between the patient responses and the chosen PASS threshold of 30. As a result, we decided to re-evaluate the whole issue according to the reviewer's remarks. Based on this reassessment, we decided to use "patient's global satisfaction to the treatment" as the criterion/anchoring question for PASS (and PDSS) . This change will have an effect on the entire responder analysis (see below).
Authors' action: Paragraph on "responder analysis" revised as follows (page 23-24): "As noted above, instead of focusing only on the statistical significance of the mean differences between treatment groups in the VAS (i.e., the mean improvement from baseline to 24 months), we will also carry out "a responder analysis". In principle, this analysis allows physicians to inform a patient of his or her chance of experiencing a clinically meaningful improvement from the treatment, both in absolute terms and in comparison, to a control group. The difference between responders and non-responders can be considered the net-benefit of the treatment. One proposed means to carry out a responder analysis relies on the assessment of the proportion of patients reaching the patient-acceptable symptom state (PASS) and the patient-disappointing symptoms state (PDSS). As no universal consensus exists on either the PASS or the PDSS in the context of SIS, we chose to anchor our responder analysis to the patient's assessment of satisfaction with the shoulder treatment outcome: Patients reporting very satisfied or satisfied will be categorized as "Responders" and those reporting very dissatisfied or dissatisfied as "Non-responders". Given the obvious coarseness of this approach, we plan to evaluate the appropriate criteria for PASS and PDSS in more detail in the future, exploring the potential contribution of, e.g., arm pain at rest and at activity, shoulder function, and night pain."
This notion also prompts a following change to our assessment of the patient satisfaction/secondary outcome measures (page 14, under the title "Patient satisfaction…"): "We elicited patients' global assessment of satisfaction to the treatment with this question: "Are you satisfied with the treatment you have received?" We used a VAS scale ranging from 0 (completely disappointed) to 100 (completely satisfied).
Additionally, we elicited patient satisfaction to the treatment outcome with the following question at each follow-up time point (Table 2) : "How satisfied are you with the outcome of your treatment?" on a 5-item scale. Participants who reported very satisfied or satisfied will be categorized as "Responders" and patients who responded very dissatisfied or dissatisfied as "Non-responders". ** The study includes three pre-specified subgroup hypotheses (page 19/20). Analyses this hypotheses are just exploring and results are rarely important (see Pocock, NEJM 2016). Nevertheless, when subgroups are included I miss a fourth hypothesis: patients on sick leave versus patients not on sick leave (Koljonen et al 2009 , Brox et al 1996 and 1999 .
Authors' response: We share the reviewer's concerns regarding the credibility (confidence in the estimates) of subgroup analyses, as also highlighted in our manuscript (page 19, under the section entitled: "Secondary analyses…"): "These secondary analyses will be supportive, explanatory and/or hypothesis generating". As for the suggestion to include a fourth hypothesis (based on sick leave), see our response to question #4. As noted, we unfortunately do not have preoperative data on sick leave status.
Authors' action: No action.
** Under limitations (page 25) it is reported that 14 patients were excluded because of A-C arthrosis or intra-articular findings. It is normally wrong to exclude patients after randomisation because it reduces the effect of randomisation, fortunately exclusion includes only a small percentage of patients. Surgeons often believe that they can observe the painful lesion during arthroscopy, but this is not possible, pain and morphology are weakly correlated. This is a pragmatic trial and it is difficult to handle various surgeons who argue that this patient has to be excluded. Still only the clinical criteria should have been applied in order to reduce bias.
Authors' response: We agree with the reviewer about the complexities of carrying out clinical (surgical) RCTs. The exclusion of patients after the first randomization (Phase I) is indeed an obvious limitation that we have discussed (page 24, under the section on "Limitations…"). However, be it also noted that although this issue potentially hampers our secondary comparison (ET vs. ASD), the patients were excluded before the second randomization (Phase II), and thus, it has no effect on our primary comparison (ASD vs. DA).
Comments from the Reviewer Number 2:
** Clinical signs of full thickness rotator cuff rupture would render exclusion. In my experience it would be impossible to ascertain a non-existing full thickness supraspinatus rupture in a patient with subacromial pain. I suggest that this is changed as I assume that the authors intend patients with Clinical signs of a major rupture resulting in marked weakness in any of the examined muscles?
Authors' response: We agree with the reviewer's remark that it is difficult/impossible to clinically ascertain a non-existing full thickness supraspinatus tear in a patient with SIS. If a patient with subacromial pain has a marked weakness of rotator cuff muscles, this is probably caused by major tendon rupture or nerve impairment. However, a seemingly normal/only slightly weak muscle strength does not rule out a (minor) cuff tear. And this is why a comprehensive clinical examination including history and physical examination was always complemented by MRA before inclusion of the patient in the trial. MRA has been shown to yield 94% sensitivity and 92% specificity for detecting a major (clinically relevant) rotator cuff tear (Lenza et al. Cochrane Database of Systematic Reviews 2013, Issue 9. Art. No.: CD009020. DOI: 10.1002/14651858.CD009020.pub2). We thank the reviewer for pointing out that adding "marked weakness in any of the examined muscles" clearly specifies the criterion.
Authors' action: The first Exclusion criterion revised as follows: "1. Full thickness tear of the rotator cuff tendons diagnosed on clinical examination (marked weakness in any of the examined muscles) or magnetic…"(page 7, under the title "Exclusion criteria").
** Later on apparently all patients underwent MRI with contrast and this was the final decision for eligibility?
Authors' response: Yes, all potentially eligible patients did indeed undergo magnetic resonance image with intra-articular contrast medium (MRA) and if any pathology (other than those "suggestive of subacromial pain syndrome") was found in MRA, patient was excluded from the study. Authors' response: Yes, fulfillment of all inclusion criteria was mandatory. Similar to any individual clinical tests for SIS, isometric (strength) tests are indeed quite unreliable (Abduction: sensitivity 55%, specificity 75%; External rotation: sensitivity 70%, specificity 50%)(e.g., Kelly et al. Clin Rehabil 2010) . In general, clinical tests with high sensitivity tend to have low specificity, and vice versa. Having said that, it has been argued that "combination of shoulder physical tests provide better accuracy, but marginally so" (Hegedus et al. BJSM 2012) . Because FIMPACT was designed as an efficacy trial, we chose our eligibility criteria so that the participants recruited would represent patients with as "pure" an SIS as possible. As we used these criterion during the eligibility screening, we prefer leaving the eligibility criteria as is. Authors' response: We thank the reviewer for pointing out this pertinent issue. Patients with substantial calcific deposits found in preoperative imaging (large enough to be considered requiring removal) were excluded from the study.
Authors' action: We have now added this as an exclusion criterion (page 7): "Substantial calcific deposits in the rotator cuff tendons found in the preoperative imaging" ** During the surgery apparently some patients were subjected to a partial bursetomy which reportedly may be a treatment for subacromial pain in itself. How is that managed in the analysis?
Authors' response: We thank the reviewer for pointing out this important issue regarding our study. It is indeed true that there is evidence to suggest that bursectomy alone provides similar outcomes to bursectomy with acromioplasty in patients with SIS (e.g., Henkus et al. JBJS-Br 2009, Donnigan The Iowa Orth J. 2011). In our FIMPACT trial, bursa tissue was addressed (either bluntly stretched with troachar or resected) only if adequate visualisation of the tendons could not be achieved without it. Resection was kept minimal and only on the tendon side of the bursa. We believe that this kind of minimal resection of bursa has no true clinical effect. Furthermore, we felt that reliable visualisation of the rotator tendon insertions was more important than possible effect of a small bursa resection.
Authors' action: No action. ** Was successful blinding controlled and assured?
Authors' response: Yes, in the two operative groups, patients were asked to guess whether they had undergone ASD or DA (page 15, para. entitled "Patients' perception of operative treatment-group assignment") at the three month follow-up. Regarding "assurance" (of successful blinding), all patients still remain blind to their treatment group (except of those who have requested unblinding due to persisting symptoms).
** "adequate relief of symptoms" at 6 months would allow crossover and change of treatment. If for instance a patients that underwent ASD was unsatisfied with the outcome, in what way was then treatment changed? Was the patient excluded or unblinded and regarded as a failure? How could blinding of the assessor be continued in such a situation?
Authors' response: We addressed the clinical scenario outlined above very pragmatically: If a patient was not satisfied with the outcome of surgery, he/she was referred to physiotherapy until he/she requested unblinding. If no ASD was carried out (DA group), then ASD was offered. If, in turn, the unblinding proved that the patient had undergone ASD, we offered extended physiotherapy. In both of these occasions, the unblinding was documented.
As for the blinding of the outcome assessors, be it noted here that all our primary outcomes are patient-reported outcome measures. In addition, the designated physiotherapists carrying out the follow-up clinical examinations were different from those treating the participants and were also instructed not to inquire about group assignment/unblinding. Finally, all follow-up examinations were carried out with participants wearing a t-shirt.
Authors' action: Prompted by these attentive comments, we have added a sentence explaining our protocol for dealing with participants who had undergone ASD as follows (page 12, 1st para.): "If the participant was allocated to DA group, ASD was then offered. If the participant had undergone ASD, he/she was offered extended physiotherapy."
Similarly, the section on follow-up assessments was revised as follows (page 15-16, last three to 1st three lines): "…in addition to which they were also assessed clinically at 6 and 24 months (and 5 and 10 years) post randomisation by a study physiotherapist unaware of treatment allocation, treatment given or possible unblinding. Outcome assessors were instructed not to inquire anything about prior treatment. Further, all follow-up examinations were carried out with participants wearing a t-shirt." ** How was inadequate relief of symptoms determined?
Authors' response: Thank you for this attentive remark. We had no pre-specified criteria for "inadequate relief of symptoms" (debilitating symptoms). Rather, we left it to the participants and the study physicians' clinical judgment to make this call.
Authors' action: We have now revised this section as follows (page 12, 1st para.): "No pre-specified criteria were used for determining "inadequate relief of symptoms/debilitating symptoms", rather it was left to the participants and the study physicians to make the clinical judgment together."
Comments from the Reviewer Number 3:
** Protocol appears to have been published after the significant portion of the project has been completed as some data appears to have been analysed already, Like on page 25 first paragraph, "Despite thorough preoperative screening...... (n=13)). Does it need to be included.
Authors' response: The reviewer is indeed correct in pointing out that significant portion of the project is already completed (actually, we are getting ready to start the actual data analysis). As for the section pointed out by the reviewer, we agree that this detail could well be omitted from the protocol (and published in the actual study report). However, as we feel that providing this data (number of preoperative exclusions) is crucially important (an obvious limitation of our trial), we felt that entering into this discussion here (in the protocol) will save some precious space to be used for other purposes in the actual study report soon to be written.
